Dissecting reactivity of clerocidin toward common buffer systems by means of selected drug analogues

Chemical Research in Toxicology

Volumn 18, Issue 1, 2005, Pages 35-40

  Richter, Sara N ^a   Fabris, Daniele ^b   Moro, Stefano ^a   Palumbo, Manlio ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF MARYLAND BALTIMORE COUNTY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUFFER; CARBONYL DERIVATIVE; CLEROCIDIN; DRUG ANALOG; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL REACTION KINETICS; DRUG STRUCTURE; HYDROGEN BOND; STRUCTURE ANALYSIS; TANDEM MASS SPECTROMETRY; THERMODYNAMICS;

ALDEHYDES; DITERPENES; DRUG INTERACTIONS; ETHYLENE OXIDE; PHOSPHATES; SCHIFF BASES; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; THERMODYNAMICS; TROMETHAMINE;

EID: 12144261538     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx049858i     Document Type: Article

References (23)

1. Pritchard, J. F., Jurima-Romet, M., Reimer, M. L., Mortimer, E., Rolfe, B., and Cayen, M. N. (2003) Making better drugs: Decision gates in nonclinical drug development. Nat. Rev. Drug Discovery 2, 542-553.
2. Ferguson, W. J., Braunschweiger, K. I., Braunschweiger, W. R., Smith, J. R., McCormick, J. J., Wasmann, C. C., Jarvis, N. P., Bell, D. H., and Good, N. E. (1980) Hydrogen ion buffers for biological research. Anal. Biochem. 104, 300-310.
3. Good, N. E., and Izawa, S. (1972) Hydrogen ion buffers. Methods Enzymol. 24, 53-68.
4. Good, N. E., Winget, G. D., Winter, W., Connolly, T. N., Izawa, S., and Singh, R. M. (1966) Hydrogen ion buffers for biological research. Biochemistry 5, 467-477.
5. Nassar, A. E., and Talaat, R. E. (2004) Strategies for dealing with metabolite elucidation in drug discovery and development. Drug Discovery Today 9, 317-327.
6. Nassar, A. E., and Lopez-Anaya, A. (2004) Strategies for dealing with reactive intermediates in drug discovery and development. Curr. Opin. Drug Discovery Dev. 7, 126-136.
7. Bugrim, A., Nikolskaya, T., and Nikolsky, Y. (2004) Early prediction of drug metabolism and toxicity: Systems biology approach and modeling. Drug Discovery Today 9, 127-135.
8. Kawada, S., Yamashita, Y., Fujii, N., and Nakano, H. (1991) Induction of a heat-stabletopoisomerase II-DNA cleavable complex by nonintercalative terpenoides, terpentecin and clerocidin. Cancer Res. 51, 2922-2925.
9. Kawada, S. Z., Yamashita, Y., Uosaki, Y., Gomi, K., Iwasaki, T., Takiguchi, T., and Nakano, H. (1992) UCT4B, a new antitumor antibiotic with topoisomerase II mediated DNA cleavage activity, from Streptomyces sp. J. Antibiot. Tokyo 45, 1182-1184.
10. Kawada, S., Yamashita, Y., Ochiai, K., Ando, K., Iwasaki, T., Takiguchi, T., and Nakano, H. (1995) Terpentecin and UCT4B, new family of topoisomerase II targeting antitumor antibiotics produced by Streptomyces: Producing organism, fermentation and large scale purification. J. Antibiot. Tokyo 48, 211-216.
11. Binaschi, M., Zagotto, G., Palumbo, M., Zunino, F., Farinosi, R., and Capranico, G. (1997) Irreversible and reversible topoisomerase II DNA cleavage stimulated by clerocidin: Sequence specificity and structural drug determinants. Cancer Res. 57, 1710-1716.
12. Borgnetto, M. E., Tinelli, S., Carminati, L., and Capranico, G. (1999) Genomic sites of topoisomerase II activity determined by comparing DNA breakage enhanced by three distinct poisons. J. Mol. Biol. 285, 545-554.
13. Gatto, B., Richter, S., Moro, S., Capranico, G., and Palumbo, M. (2001) The topoisomerase II poison clerocidin alkylates nonpaired guanines of DNA: implications for irreversible stimulation of DNA cleavage. Nucleic Acids Res. 29, 4224-4230.
14. Richter, S., Gatto, B., Fabris, D., Takao, K., Kobayashi, S., and Palumbo, M. (2003) Clerocidin alkylates DNA through its epoxide function. Evidence for a fine-tuned mechanism of action. Nucleic Acids Res. 31, 5149-5156.
15. Richter, S., Fabris, D., Binaschi, M., Gatto, B., Capranico, G., and Palumbo, M. (2004) Effects of common buffer systems on drug activity: The case of clerocidin. Chem. Res. Toxicol. 17, 492-501.
16. Andersen, N. R., Lorck, H. O., and Rasmussen, P. R. (1983) Fermentation, isolation and characterization of antibiotic PR-1350. J. Antibiot. Tokyo 36, 753-760.
17. Andersen, N., Lork, H., and Rassmussen, P. (1984) The relative and absolute configuration of clerocidin and its cometabolites. Tetrahedron Lett. 25, 469-472.
18. Andersen, N., and Rasmussen, P. (1984) The costitution of clerocidin. A new antibiotic isolated from Oidiodendron truncatum. Tetrahedron Lett. 25, 465-468.
19. Nakajima, N., Okazaki, T., Iwado, S., Kinoshita, T., and Haneishi, T. (1989) New diterpenoid antibiotics, Spirocardins A and B. J. Antibiot. Tokyo 42, 1741-1748.
20. Molecular Operating Environment (MOE 2002.03), Chemical Computing Group, Inc., Montreal, Quebec, Canada.
21. Halgren, T. (1996) Merck molecular force field. IV. Conformational energies and geometries for MMFF94. J. Comput. Chem. 17, 587-615.
22. Halgren, T. (1999) MMFF VII. Characterization of MMFF94, MMFF94s, and other widely available force fields for conformational energies and for intermolecular-interaction energies and geometries. J. Comput. Chem. 20, 730-748.
23. Spartan O2, Wavefuntion Inc., Irvine, CA.